Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery
暂无分享,去创建一个
B. Clotet | J. Martinez-Picado | E. Negredo | M. Massanella | J. Blanco | J. Carrillo | M. Buzón | J. Puig | N. Pérez-Álvarez | M. Puertas
[1] J. Benito,et al. Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir , 2012, AIDS.
[2] B. Clotet,et al. Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study , 2012, Antiviral therapy.
[3] S. Lewin,et al. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. , 2011, The Journal of infectious diseases.
[4] M. Lederman,et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. , 2011, The Journal of infectious diseases.
[5] M. Clerici,et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. , 2011, Blood.
[6] D. Boulware,et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. , 2011, The Journal of infectious diseases.
[7] P. D. de Bakker,et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. , 2011, The Journal of clinical investigation.
[8] J. Reynes,et al. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. , 2011, Blood.
[9] Jeffrey N. Martin,et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. , 2011, The Journal of infectious diseases.
[10] G. Carcelain,et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. , 2011, Blood.
[11] A. d’Arminio Monforte,et al. Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy , 2011, PloS one.
[12] Jeffrey N. Martin,et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. , 2011, The Journal of infectious diseases.
[13] M. Si-Tahar,et al. Innate Sensing of HIV-Infected Cells , 2011, PLoS pathogens.
[14] A. Sharrett,et al. T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women , 2011, The Journal of infectious diseases.
[15] C. B. Hare,et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.
[16] P. Mas,et al. Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain , 2010, Proceedings of the National Academy of Sciences.
[17] M. Lederman,et al. The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.
[18] F. Villarroya,et al. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] B. Clotet,et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART , 2010, AIDS.
[20] B. Clotet,et al. Changes in T-cell subsets in HIV–HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment , 2010, Antiviral therapy.
[21] Sarah Palmer,et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.
[22] Giulia Marchetti,et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] V. Appay,et al. Phenotype and function of human T lymphocyte subsets: Consensus and issues , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[24] J. Brenchley,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.
[25] M. Lederman,et al. Interferon-α differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection , 2006 .
[26] M. Lederman,et al. Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. , 2006, AIDS.
[27] A. Flahault,et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. , 2005, The Journal of infectious diseases.
[28] J. Barretina,et al. R5 HIV gp120‐mediated cellular contacts induce the death of single CCR5‐expressing CD4 T cells by a gp41‐dependent mechanism , 2004, Journal of leukocyte biology.
[29] J. Barretina,et al. Immunological and virological study of enfuvirtide-treated HIV-positive patients , 2004, AIDS.
[30] M. Kazatchkine,et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.
[31] C. Sabin,et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. , 1996, AIDS.
[32] J. Margolick,et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. , 1994, The Journal of infectious diseases.